細胞名稱

NK-92暫不供應人惡性非霍奇金淋巴瘤患者的自然殺傷細胞,

描述

NK-92是從一位患有急進性非霍奇金淋巴瘤的50歲白人男性外周血單核細胞衍生來的一株白細胞介素-2依賴型NK細胞株。 這株細胞對很多惡性細胞有細胞毒性；鉻釋放試驗顯示它能殺死K562和Daudi細胞。 NK-92細胞(經過照射以防止增殖)可以有效地用于血液中白血病的體外免疫清掃而不危及血細胞的功能。 NK-92細胞有以下特征： CD2, CD7, CD11a, CD28, CD45, CD54表面標記陽性，CD56亮；CD1, CD3, CD4, CD5, CD8, CD10, CD14, CD16, CD19, CD20, CD23, CD34和HLA-DR表面標記陰性。

動物種別

人

性別

男

組織來源

惡性非霍奇金淋巴瘤患者的自然殺傷細胞,

形態

淋巴母細胞

培養基和添加劑

MEMα-培養基(GIBCO,貨號12000022，添加NaHCO3 1.5g/L，肌醇 43.2mg/L, * 8.82mg/L,100-200單位/ml重組 IL-2,β-巰基乙醇 7.8mg/L)，90%；優質胎牛血清，10%。 氣相：空氣，95%；二氧化碳，5%。 溫度：37攝氏度。

供應限制

REFERENCE

Gong JH , et al. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8: 652-658, 1994. PubMed: 8152260 Klingemann HG , et al. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biol. Blood Marrow Transplant. 2: 68-75, 1996. PubMed: 9118301 Tam YK , et al. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum. Gene Ther. 10: 1359-1373, 1999. PubMed: 10365666 Klingemann HG , Miyagawa B . Purging of malignant cells from blood after short ex vivo incubation with NK-92 cells. Blood 87: 4913-1914, 1996. PubMed: 8639869 Komatsu F , Kajiwara M . Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells. Oncol. Res. 10: 483-489, 1998. PubMed: 10338151 Yan Y , et al. Antileukemia activity of a natural killer cell line against human leukemias. Clin. Cancer Res. 4: 2859-2868, 1998. PubMed: 9829753 Maki G , et al. Induction of sensitivity to NK-mediated cytotoxicity by TNF-alpha treatment: possible role of ICAM-3 and CD44. Leukemia 12: 1565-1572, 1998. PubMed: 9766501 Nagashima S , et al. Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. Blood 91: 3850-3861, 1998. PubMed: 9573023 Tam YK , et al. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J. Hematother. 8: 281-290, 1999. PubMed: 10417052